G. Borg

Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial.

U. Brodin, E. Allander, G. Borg, 1991, The Journal of rheumatology.

Disease-modifying anti-rheumatic drug therapy. An expensive therapy despite inexpensive drugs.

E. Allander, G. Borg, J. Goobar, 1990, Scandinavian journal of rheumatology.

Auranofin (SK&F) in early rheumatoid arthritis: results from a 24-month double-blind, placebo-controlled study. Effect on clinical and biochemical assessments.

U. Brodin, G. Borg, E. Berg, 1989, Scandinavian journal of rheumatology.

Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.

U. Brodin, H. Pettersson, G. Borg, 1995, The Journal of rheumatology.

Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.

U. Brodin, H. Pettersson, E. Allander, 1988, The Journal of rheumatology.